springworks merck - Search News

News

Merck KGaA to Buy US Drugmaker Springworks

Germany's Merck Agrees to Buy US Biotech SpringWorks Therapeutics for Almost $4B

KEY TAKEAWAYS German drug company Merck KGaA said Monday it has struck a deal to buy U.S. biotech firm SpringWorks Therapeutics for around $3.9 billion, expanding its portfolio of rare disease and cancer treatments.

Bloomberg on MSN · 3h

Merck KGaA to Buy US Biotech Springworks for $3.9 Billion

Merck KGaA agreed to buy SpringWorks Therapeutics Inc., a maker of medicines for cancer and rare diseases, to boost its health-care division. The purchase price of $47 per share in cash represents an equity value of about $3.

Pharmaceutical Technology · 28m

Merck KGaA strikes $3.9bn deal for SpringWorks

Merck has moved to strengthen its position in oncology and rare diseases with a $3.9bn agreement to acquire SpringWorks Therapeutics.

Merck KGaA, Darmstadt, Germany, to Acquire US Biopharma Company SpringWorks Therapeutics to Accelerate Sustainable Growth of Healthcare Business

Merck KGaA, Darmstadt, Germany (DAX: MRK), a leading science and technology company, and SpringWorks Therapeutics, Inc.

Devdiscourse22h

Global Health Updates: From Mergers to Measles and Medicine

The latest health-related developments include Merck's acquisition talks with SpringWorks, disbandment of a US Justice ...

Fierce Pharma2d

Merck KGaA confirms late-stage talks with SpringWorks about $3.5B buyout

Merck KGaA’s protracted pursuit of SpringWorks Therapeutics may be nearing its endgame. | Merck KGaA’s protracted pursuit of ...

DPA International on MSN2d

German pharma giant Merck close to takeover of US cancer specialist

Germany's Merck is on the verge of a billion-euro takeover of US biopharmaceutical company Springworks Therapeutics, with the ...

Devdiscourse1d

Health Headlines: From Measles Concerns to Pharma Developments

Gilead Sciences reports profits but mixed revenue; Merck is in talks to acquire SpringWorks for $3.5 billion; measles cases ...

Positive opinion for Ogsiveo would de-risk SpringWorks deal, says Barclays

Barclays notes that SpringWorks Therapeutics’ Ogsiveo was included on today’s Committee for Medicinal Products for Human Use agenda, which could lead to a positive opinion for ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results